Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Raymond James

Improved Costs, Reels Growth, Attractive Multiples: What 6 Analysts Are Saying About Meta Platforms Post Earnings

Shares of social media and metaverse company Meta Platforms Inc (NASDAQ: FB) traded higher Wednesday after market close. The move came after the company reported first-quarter financial results. Here are the key takeaways from the earnings report from analysts.

Raymond James Maintains Outperform Rating for Hologic: Here's What You Need To Know

Raymond James Maintains Outperform Rating for Hologic: Here's What You Need To Know

Raymond James has decided to maintain its Outperform rating of Hologic (NASDAQ:HOLX) and lower its price target from $84.00 to $83.00. Shares of Hologic are trading down 2.08% over the last 24 hours, at $69.37 per share. A move to $83.00 would account for a 19.65% increase from the current…

Occidental Petroleum Whale Trades For April 28

Occidental Petroleum Whale Trades For April 28

Someone with a lot of money to spend has taken a bearish stance on Occidental Petroleum (NYSE:OXY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Chipotle Can Navigate Food Cost Concerns, Menu Price Increases: 4 Analysts React To Earnings Report

Rising food costs, menu price increases and store growth were the big topics highlighted by analysts who cover restaurant company Chipotle Mexican Grill, Inc. (NYSE: CMG). Here are the key analyst takeaways.

Raymond James Maintains Strong Buy Rating for Mohawk Industries: Here's What You Need To Know

Raymond James has decided to maintain its Strong Buy rating of Mohawk Industries (NYSE:MHK) and lower its price target from $220.00 to $190.00. Shares of Mohawk Industries are trading up 0.59% over the last 24 hours, at $125.44 per share.

Edwards Lifesciences Clocks 10% Top-Line Growth In Q1; Forecasts Lower Than Expected Q2 Sales

Edwards Lifesciences Corp (NYSE:EW) posted a Q1 adjusted EPS of $0.60, compared to $0.54 posted a year ago and beating the consensus of $0.57. Sales increased 10% to $1.34 billion (underlying 13%), beating the consensus of $1.31 billion. Transcatheter aortic valve replacement sales grew to $881 million, up 11%. Globally, the company's…

Analysts Share Their View On Activision Blizzard Post Q1 Performance

Analysts offered their views on Activision Blizzard, Inc (NASDAQ:ATVI) post Q1 FY22 results. Raymond James saw ATVI's Q1 results significantly below expectations, driven by continued weakness in Call of Duty and a low ebb of content in Blizzard. It continued to see sizable headwinds for Call of Duty through the rest of the year until the anticipated release…

inkl

Read news from The Economist, FT, and more,
with one subscription

Check Out What Whales Are Doing With JNJ

Check Out What Whales Are Doing With JNJ

Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Raymond James Lists Marvell's Sources Of Growth, Profitability Leading To Upgrade

Raymond James Lists Marvell's Sources Of Growth, Profitability Leading To Upgrade

Two analysts re-rated Marvell Technology Inc (NASDAQ: MRVL) today.

Here's Why Raymond James Sees 75.4% Upside In AMD; Upgrades To Strong Buy

Here's Why Raymond James Sees 75.4% Upside In AMD; Upgrades To Strong Buy

Raymond James analyst Chris Caso upgraded Advanced Micro Devices Inc (NASDAQ:AMD) to Strong Buy from Outperform with a $160 price target. The price target implies a 75.4% upside. As Caso became more concerned about cycle risks, given the potential for slowing consumer demand and elevated inventory levels at customers, he favored those semi companies with…

Why AMD Shares Are Trading Higher Today

Why AMD Shares Are Trading Higher Today

Advanced Micro Devices, Inc. (NASDAQ: AMD) shares are trading higher Monday following positive analyst coverage from Raymond James. Raymond James analyst Chris Caso upgraded the stock from Outperform to Strong Buy and announced a $160 price target.

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

Analysts Think Intuitive Surgical Painted 'Cautious Picture' For Procedure Guidance

Analysts Think Intuitive Surgical Painted 'Cautious Picture' For Procedure Guidance

Wells Fargo writes that despite the beat in Q1, Intuitive Surgical Inc (NASDAQ:ISRG) sounded cautious on U.S. capital placements, given rising interest rates and inflationary pressure at hospitals. "We think this commentary was partly driven by the need to recalibrate Street models for fewer trade-ins as the number of legacy Si systems declines. Overall,…

These Netflix Analysts Aren't Confident Of A Turnaround Within The Next 18 Months

These Netflix Analysts Aren't Confident Of A Turnaround Within The Next 18 Months

Netflix Inc (NASDAQ: NFLX) reported a revenue miss and a loss of net paid adds for the first quarter.

Get all your
news in one place.

100's of premium titles.
One news app.

Analysts Bump Up CSX Price Target Post Q1 Results

CSX Corp's (NASDAQ:CSX) price target has been raised by two analysts post Q1 results. Raymond James analyst Patrick Tyler Brown raised CSX’s price target to $40 (an upside of 10%) from $39 while maintaining the Outperform rating on the shares. The analyst states that CSX continues to execute its PSR initiatives to drive operational improvement,…

What Does Raymond James, Wells Fargo Have To Say On Abbott's Q1 Earnings

Raymond James thinks Abbott Laboratories' (NYSE: ABT) 1Q results were solid and demonstrated the durable nature of ABT's portfolio, as three out of four business segments grew over 10% organically, with Nutrition growing 8%

Johnson & Johnson Whale Trades For April 20

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 11 strange trades.

Abbott Clocks Q1 COVID-19 Test Sales Of $3.3B, Reaffirms FY22 EPS Outlook

Abbott Laboratories (NYSE:ABT) has reported Q1 FY22 adjusted EPS of $1.73, up 31.1% Y/Y, better than the consensus of $1.47 and the management guidance of $1.50. Q1 sales of $11.9 billion increased 13.8% on a reported basis and 17.5% on an organic basis, beating the consensus of $11.02 billion. Worldwide sales, excluding…

Get all your
news in one place.

100's of premium titles.
One news app.

Raymond James Lists Key Takeaways From Qualtrics' Proxy Filing

Qualtrics International Inc's (NASDAQ:XM) April 15 proxy filing also disclosed new ACV and retention metrics pertinent to investors, Raymond James observed. Qualtrics added $365.1 million in new software ACV billings in 2021, effectively aligning with the target performance level of $365.0 million. Total research services billing of $160.1 million also were effectively in-line…

Raymond James Says Coupa Beat Oracle and SAP In Software Market Share Gains

Raymond James observed Gartner's report that saw Coupa Software Inc (NASDAQ: COUP) gain ~135 points of software market share in procurement, with a growth of 35%, more than double the industry average at ~16%.

Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022

Raymond James Thinks Med Tech Investors are Somewhat 'Paralyzed' Ahead Of Q1 Earnings

Raymond James has outlined its expectations for next week when Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT), and Intuitive Surgical Inc (NASDAQ:ISRG) will report Q1 FY22 earnings. Analysts believe that the Med Tech investors have become somewhat 'paralyzed' given the macro/factor-driven concerns. On the macro, investor attention seems to be focused less on revenue growth and more…

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Raymond James Maintains Strong Buy Rating for Copa Holdings, Lowers Price Target To $110

Raymond James has decided to maintain its Strong Buy rating of Copa Holdings (NYSE:CPA) and lower its price target from $115.00 to $110.00. Shares of Copa Holdings are trading up 2.68% over the last 24 hours, at $78.04 per share.

Raymond James Cuts Copa's Price Target By 4%

Raymond James analyst Savanthi Syth lowered the price target on Copa Holdings (NYSE:CPA) to $110 (an upside of 42%) from $115 while maintaining the Strong Buy rating on the shares. Copa is a Panamanian holding company consisting of Copa Airlines and Copa Colombia. The analyst revised the forecast to reflect higher fuel price forecasts, particularly…

1 … 9 10 11 12

People

Barton Crockett

Justin Patterson

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Intel Corporation

Wikimedia Commons

Activision Blizzard

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

398,236 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play